Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or ...

Novartis has discontinued two undisclosed programs under its current partership with Voyager, the biotech announced last ...

The tickets could go to the lipid-lowering pill enlicitide decanoate and the antibody-drug conjugate sacituzumab tirumotecan, ...

The Greater Philadelphia life sciences ecosystem has over 1,200 life sciences establishments, including 450 biotech research ...

Clarity on employment terms is essential to protect careers. In this column, Kaye/Bassman’s Michael Pietrack speaks to ...

San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory ...

Despite falling short of its primary Phase II objective, Nektar plans to push its T cell stimulator rezpeg into Phase III ...

For one, interest rates are finally going down, with the Federal Reserve executing its latest cut on December 10. And ...

Addition joins a growing list of launches this year, following in the footsteps of startups like Crystalys Therapeutics and ...

Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal ...

These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down ...

Representatives of companies including AbbVie, Eli Lilly, Johnson & Johnson and Merck have voiced concerns about the FDA’s ...